

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (canceled) A method of inhibiting proliferation of malignant cells, comprising administering to the malignant cell at least one E-domain peptide agent.

Claim 2. (canceled) The method of claim 1, wherein the E-domain peptide agent is selected from the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

Claim 3. (canceled) The method of claim 2, wherein the E-domain peptide is an E-domain peptide of a rainbow trout.

Claim 4. (canceled) The method of claim 3, wherein the trout E-domain peptide is selected from the group consisting of: Ea-2 domain peptide (SEQ ID NO:2) and Ea-4 domain peptide (SEQ ID NO:4).

Claim 5. (canceled) The method of claim 4, wherein the E-domain peptide agent is administered in a pharmaceutical composition.

Claim 6. (original) A method of inhibiting the proliferation of malignant cells, comprising administering to the malignant cells a nucleic acid encoding an E-domain peptide agent.

Claim 7. (original) The method of Claim 6, wherein the E-domain peptide agent is selected from the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

Claim 8. (original) The method of claim 7, wherein the E-domain peptide is an E-domain peptide of a rainbow trout.

Claim 9. (original) The method of claim 8, wherein the trout E-domain peptide is selected from the group consisting of: Ea-2 domain peptide (SEQ ID NO:2) and Ea-4 domain peptide (SEQ ID NO:4).

Claim 10. (original) The method of claim 9, wherein the nucleic acid encoding the E-domain peptide is administered in a pharmaceutical composition.

Claim 11. (canceled) A method for reducing the invasiveness of malignant cells, comprising administering to the malignant cells an E-domain peptide.

Claim 12. (canceled) The method of claim 11, wherein the E-domain peptide agent is selected from the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

Claim 13. (canceled) The method of claim 12, wherein the E-domain peptide is an E-domain peptide of a rainbow trout.

Claim 14. (canceled) The method of claim 13, wherein the trout E-domain peptide is selected from the group consisting of: Ea-2 domain peptide (SEQ ID NO:2) and Ea-4

domain peptide (SEQ ID NO:4).

Claim 15. (canceled) The method of claim 14 wherein the E-domain peptide agent is administered in a pharmaceutical composition.

Claim 16. (original) A method for reducing the invasiveness of malignant cells, comprising administering to the malignant cells a nucleic acid encoding an E-domain peptide agent.

Claim 17. (original) The method of claim 16, wherein the E-domain peptide agent is selected from the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

Claim 18. (original) The method of claim 17, wherein the E-domain peptide is an E-domain peptide of a rainbow trout.

Claim 19. (original) The method of claim 18, wherein the trout E-domain peptide is selected from the group consisting of: Ea-2 domain peptide (SEQ ID NO:2) and Ea-4 domain peptide (SEQ ID NO:4).

Claim 20. (original) The method of claim 19, wherein the nucleic acid encoding the E-domain peptide is administered in a pharmaceutical composition.

Claim 21. (new) A method of inhibiting proliferation of malignant cells, comprising administering to the malignant cell at least one E-domain peptide agent, wherein the E-domain peptide agent is selected from the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

Claim 22. (new) A method of reducing the invasiveness of malignant cells, comprising administering to the malignant cells an E-domain peptide agent, wherein the E-domain peptide agent is selected from the group consisting of: a trout E-domain peptide, an E-domain peptide homolog, and an E-domain peptide fusion protein.

Claim 23. (new) The method of claim 22, wherein the E-domain peptide is an E-domain peptide of a rainbow trout and is selected from the group consisting of: Ea-2 domain peptide (SEQ ID NO:2) and Ea-4 domain peptide (SEQ ID NO:4), and wherein the E-domain peptide is administered in a pharmaceutical composition.